Background:Thyroid cancer (TC) is the most frequent endocrine cancer, comprising for 3-4% of all tumors. Objective: The aim of the current study was to assess the efficacy, safety, and disease-free survival of low-dose RAI (iodine-131) in patients with low-risk differentiated thyroid cancer (DTC) who had low-dose RAI for thyroid residual ablation after full or near-total thyroidectomy. Patients and methods: Between January 2013 and July 2019, 35 patients with low-risk well-differentiated thyroid cancer were investigated by the Clinical Oncology and Nuclear Department at Mansoura University Hospitals. Results: The majority of our patients (94.3%) were females. A total of 34 (97.1%) patients had papillary thyroid cancer and 1 (2.8 %) patient had follicular thyroid carcinoma. All patients were Stage I; 13 (37.1%) patients were T1, and 22 (62.9%) patients were T2 thyroid carcinoma. All patients had pathologically negative lymph nodes and 8 (22.8%) patients had complete thyroidectomy with block neck dissection (BND), whereas the remaining 27 (77.1%) patients had total thyroidectomy without BND. Conclusion: Low-dose radioactive iodine ablation following surgery is an effective approach for treating low-risk DTC, because it decreases the side effects while preserving a good quality of life.